- Home
- CGEM vs SBET Comparison
CGEM vs SBET Comparison
Compare CGEM & SBET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEM | SBET |
|---|---|---|
| Founded | 2016 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.4B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CGEM | SBET |
|---|---|---|
| Price | $17.59 | $6.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $30.13 | $18.71 |
| AVG Volume (30 Days) | 510.9K | ★ 7.7M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $28,055,000.00 |
| Revenue This Year | N/A | $105.19 |
| Revenue Next Year | $5.20 | $13.53 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 666.04 |
| 52 Week Low | $5.68 | $4.46 |
| 52 Week High | $19.43 | $24.55 |
Technical Indicators
Market Signals| Indicator | CGEM | SBET |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 55.50 |
| Support Level | $17.19 | $6.05 |
| Resistance Level | $19.10 | $6.53 |
| Average True Range (ATR) | 0.89 | 0.35 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 81.78 | 71.16 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About SBET SharpLink Gaming Ltd.
Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.